Results 51 to 60 of about 69,036 (281)

Levodopa versus non-levodopa brain language fMRI in Parkinson’s disease [PDF]

open access: yesEinstein (São Paulo), 2012
Objective: To identify the effect of levodopa in language areas inParkinson’s disease patients. Methods: We evaluated 50 patientswith mild to moderate Parkinson’s disease, age and gender pairedto 47 healthy volunteers.
Paula Ricci Arantes   +7 more
doaj  

Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson’s disease: study protocol for the ISTRA ADJUST PD randomized, controlled study

open access: yesBMC Neurology, 2022
Background Levodopa remains the most effective symptomatic treatment for Parkinson’s disease (PD) more than 50 years after its clinical introduction. However, the onset of motor complications can limit pharmacological intervention with levodopa, which ...
Taku Hatano   +25 more
doaj   +1 more source

Management of rapid eye movement sleep behavior disorder in patients with Parkinson's disease [PDF]

open access: yes, 2016
Among all of the devastating effects that Parkinson’s disease (PD) has on an individual, sleep dysfunction is one that can have a profound effect on the entire family of the patient. The most potentially destructive of these sleep syndromes being that of
Jeffries, Michael
core   +1 more source

Validity of a Wearable Digital Insole for Assessing Gait ON and OFF in Parkinson's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Gait impairment is a distinctive symptom of Parkinson's disease that negatively impact mobility. We assessed the validity of wearable digital insoles against a validated reference gait analysis system for measuring select gait characteristics in patients with Parkinson's disease. Methods A comparative analysis between digital insoles
Deborah A. Hall   +16 more
wiley   +1 more source

Baseline Regional Cholinergic Denervation Predicts Cognitive Trajectories in Moderate Parkinson Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cognitive decline is a disabling and variable feature of Parkinson disease (PD). While cholinergic system degeneration is linked to cognitive impairments in PD, most prior research reported cross‐sectional associations. We aimed to fill this gap by investigating whether baseline regional cerebral vesicular acetylcholine transporter ...
Taylor Brown   +6 more
wiley   +1 more source

Levodopa acts centrally to induce an antinociceptive action against colonic distension through activation of D2 dopamine receptors and the orexinergic system in the brain in conscious rats

open access: yesJournal of Pharmacological Sciences, 2016
Levodopa possesses antinociceptive actions against several somatic pain conditions. However, we do not know at this moment whether levodopa is also effective to visceral pain.
Toshikatsu Okumura   +5 more
doaj   +1 more source

Comparative adsorption of levodopa from aqueous solution on different activated carbons [PDF]

open access: yes, 2009
Adsorption on activated carbon has been successfully used in wastewater and drinking water treatment plants for the removal of various pollutants. Among them, pharmaceutical compounds have become a growing issue. The present study has focused on levodopa
Delmas, Henri   +4 more
core   +1 more source

CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Imaging and postmortem studies indicate that abnormalities in monoaminergic neurotransmission contribute to cognitive impairment in Parkinson's disease (PD). However, it remains uncertain if cerebrospinal fluid (CSF) monoamine metabolites can serve as biomarkers of cognitive decline in early PD.
Jing‐Yu Shao   +7 more
wiley   +1 more source

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective

open access: yesNeuropsychiatric Disease and Treatment, 2008
David J BrooksDivision of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UKAbstract: After 40 years of clinical experience, levodopa remains the gold standard treatment for Parkinson’s disease (PD) despite ...
David J Brooks
doaj  

Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease

open access: yeseNeurologicalSci, 2018
We conducted a phase I study investigating the efficacy, safety, and tolerability of ONO-2160, a newly developed levodopa pro-drug, and carbidopa compared with levodopa and carbidopa to stabilize levodopa plasma concentration fluctuations in Japanese ...
Masahiro Nomoto   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy